Concise Prescribing Info
HTN, CHF, reduction of mortality after MI. Prevention of MI, stroke or CV death & reduction of need for revascularization procedures in patients w/ increased CV risk. Decrease progression of renal insufficiency in nondiabetic & diabetic overt nephropathy. Prevention of MI, stroke or CV death in diabetic patients. Reduce albumin excretion in nondiabetic & diabetic incipient nephropathy.
Dosage/Direction for Use
HTN Initially 2.5 mg once daily. Maintenance: 2.5-5 mg daily. Max: 10 mg/day. CHF Initially 1.25 mg once daily. Max: 10 mg/day. Treatment of MI Initially 2 single doses of 2.5 mg (morning & evening). Max: 10 mg/day. Prevention of MI, stroke or CV death Initially 2.5 mg once daily. Maintenance: 10 mg/day. Nephropathy Initially 1.25 mg once daily. Max: 5 mg/day. Diabetic & nondiabetic nephropathy Initially 1.25 mg once daily. May be increased up to a maintenance dose of 5 mg once daily. Elderly Initially 1.25 mg daily.
May be taken with or without food.
History of angioneurotic oedema. Haemodynamically relevant stenosis of the renal artery, bilateral or unilateral in the single kidney. Hypotension or labile circulatory condition. Co-administration w/ aliskiren-containing drugs in patients w/ diabetes or moderate to severe renal impairment. Co-administration w/ angiotensin II receptor blockers in patients w/ diabetic nephropathy.  Extracorporeal treatments leading to blood contact w/ negatively charged surfaces. Pregnancy.
Special Precautions
Increased risk of hypotension, hyperkalemia & changes in renal function in combination w/ angiotensin II receptor blockers or aliskiren. Hyperstimulated renin-angiotensin system. Patients w/ liver disease; at particular risk from a pronounced reduction in BP. Renal function, electrolyte & haematological monitoring. May impair ability to drive or operate machinery. Lactation. Elderly.
Adverse Reactions
Headache, dizziness; nonproductive tickling cough, bronchitis, sinusitis, dyspnea; GI inflammation, rash in particular maculo-papular, muscle spasms, myalgia; increased blood K; hypotension, decreased orthostatic BP, syncope; chest pain, fatigue.
Drug Interactions
Dialysis or haemofiltration w/ certain high-flux membranes & low-density lipoprotein apheresis w/ dextran sulfate. K salts, K-retaining diuretics, antihypertensives, nitrates, TCAs, anesth, vasopressor sympathomimetics, allopurinol, immunosuppressants, corticosteroids, procainamide, cytostatics, lithium salts, antidiabetics, vildagliptin, NSAIDs, acetylsalicylic acid, heparin, alcohol, salt.
ATC Classification
C09AA05 - ramipril ; Belongs to the class of ACE inhibitors. Used in the treatment of cardiovascular disease.
Tritace tab 10 mg
3 × 10's
Tritace tab 2.5 mg
10 × 10's
Tritace tab 5 mg
3 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in